Cepharanthine as an effective small cell lung cancer inhibitor: integrated insights from network pharmacology, RNA sequencing, and experimental validation
This study identifies CE as a potential therapeutic agent for SCLC, acting through the suppression of cholesterol synthesis, and uncovers novel therapeutic targets for the treatment of this aggressive cancer.
Authors
- Fugui Li (ORCID: https://orcid.org/0000-0003-1768-2696)
- Mingfang Ji (ORCID: https://orcid.org/0000-0003-4727-2858)
- Fengyun Zhao
- Zhaowei Ding
- Mengting Chen (ORCID: https://orcid.org/0000-0001-9379-6818)
Institutions
- South China Normal University (CN)
- First Affiliated Hospital of Guangzhou Medical University (CN)
- Zhongshan People's Hospital (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-11-28
- DOI
- https://doi.org/10.3389/fphar.2024.1517386
- Citations
- 3
- Primary Topic
- Cancer therapeutics and mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.70